View Filing Data

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2017	Mar. 16, 2018	Jun. 30, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	CHF Solutions, Inc.
Entity Central Index Key	0001506492
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 12.7
Entity Common Stock, Shares Outstanding		4,226,251
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 15,595	$ 1,323
Accounts receivable	545	282
Inventories	1,588	677
Other current assets	136	137
Total current assets	17,864	2,419
Property, plant and equipment, net	570	540
Intangible assets, net	0	4,302
Goodwill	0	189
Other assets	21	21
TOTAL ASSETS	18,455	7,471
Current liabilities
Accounts payable	862	1,987
Accrued compensation	1,021	909
Other current liabilities	208	364
Total current liabilities	2,091	3,260
Common stock warrant liability	0	1,843
Other liabilities	126	126
Total liabilities	2,217	5,229
Commitments and contingencies
Stockholders' equity
Preferred stock	0	0
Common stock as of December 31, 2017 and December 31, 2016, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 3,798,929 and 38,862, respectively	0	0
Additional paid-in capital	197,367	169,496
Accumulated other comprehensive income:
Foreign currency translation adjustment	1,227	1,235
Accumulated deficit	(182,356)	(168,974)
Total stockholders' equity	16,238	1,757
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	18,455	7,471
Series A Junior Participating Preferred Stock [Member]
Stockholders' equity
Preferred stock	0	0
Series B-1 Convertible Preferred Stock [Member]
Stockholders' equity
Preferred stock	0	0
Series C Convertible Preferred Stock [Member]
Stockholders' equity
Preferred stock	0	0
Series F Convertible Preferred Stock [Member]
Stockholders' equity
Preferred stock	0	0
Series D Convertible Preferred Stock [Member]
Temporary Stockholders' Equity
Series D convertible preferred stock as of December 31, 2017 and December 31, 2016, par value $0.0001 per share; authorized 0 and 900 shares, respectively, issued and outstanding 0 and 700, respectively	$ 0	$ 485

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	39,966,220	39,964,375.6
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	3,798,929	38,862
Common stock, shares outstanding (in shares)	3,798,929	38,862
Series A Junior Participating Preferred Stock [Member]
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	30,000	30,000
Preferred stock, shares outstanding (in shares)	0	0
Series B-1 Convertible Preferred Stock [Member]
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	0	1,824.4
Preferred stock, shares issued (in shares)	0	1,824.4
Preferred stock, shares outstanding (in shares)	0	1,824.4
Series C Convertible Preferred Stock [Member]
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	0	2,900
Preferred stock, shares issued (in shares)	0	2,900
Preferred stock, shares outstanding (in shares)	0	2,900
Series D Convertible Preferred Stock [Member]
Temporary Stockholders' Equity
Temporary stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Temporary stock, shares authorized (in shares)	0	900
Temporary stock, shares issued (in shares)	0	700
Temporary stock, shares outstanding (in shares)	0	700
Series F Convertible Preferred Stock [Member]
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	3,780	0
Preferred stock, shares issued (in shares)	3,780	0
Preferred stock, shares outstanding (in shares)	3,780	0

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Consolidated Statements of Operations and Comprehensive Loss [Abstract]
Net sales	$ 3,553	$ 1,289
Costs and Expenses:
Cost of goods sold	2,763	713
Selling, general and administrative	10,170	8,129
Research and development	1,481	8,109
Goodwill and intangibles impairment	3,951	0
Total costs and expenses	18,365	16,951
Loss from operations	(14,812)	(15,662)
Other income (expense):
Interest expense	0	(504)
Loss on early retirement of long-term debt	0	(500)
Other income, net	28	2
Warrant valuation expense	(67)	0
Change in fair value of warrant liability	1,475	818
Total other income (expense)	1,436	(184)
Loss before income taxes	(13,376)	(15,846)
Income tax (expense) benefit, net	(6)	54
Net loss	$ (13,382)	$ (15,792)
Basic and diluted loss per share (in dollars per share)	$ (37.51)	$ (536.12)
Weighted average shares outstanding - basic and diluted (in shares)	665	33
Other comprehensive income:
Foreign currency translation adjustment	$ (8)	$ (11)
Total comprehensive loss	$ (13,390)	$ (15,803)

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid in Capital [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2015	$ 0	$ 164,107	$ 1,246	$ (153,182)	$ 12,171
Balance (in shares) at Dec. 31, 2015	30,574
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0	0	0	(15,792)	(15,792)
Foreign currency translation adjustment	0	0	(11)	0	(11)
Stock based compensation, net	$ 0	949	0	0	949
Stock based compensation, net (in shares)	472
Issuance of preferred stock, net	$ 0	4,440	0	0	4,440
Issuance of common stock for acquisition	$ 0	0	0	0	0
Issuance of common stock for acquisition (in shares)	1,667
Conversion of preferred stock into common stock	$ 0	0	0	0	0
Conversion of preferred stock into common stock (in shares)	6,149
Balance at Dec. 31, 2016	$ 0	169,496	1,235	(168,974)	1,757
Balance (in shares) at Dec. 31, 2016	38,862
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0	0	0	(13,382)	(13,382)
Foreign currency translation adjustment	0	0	(8)	0	(8)
Stock based compensation, net	$ 0	499	0	0	499
Stock based compensation, net (in shares)	375
Issuance of common stock, net	$ 0	5,399	0	0	5,399
Issuance of common stock, net (in shares)	194,794
Issuance of preferred stock, net	$ 0	21,973	0	0	21,973
Conversion of preferred stock into common stock	$ 0	0	0	0	0
Conversion of preferred stock into common stock (in shares)	3,564,898
Balance at Dec. 31, 2017	$ 0	$ 197,367	$ 1,227	$ (182,356)	$ 16,238
Balance (in shares) at Dec. 31, 2017	3,798,929

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Operating Activities
Net loss	$ (13,382)	$ (15,792)
Adjustments to reconcile net loss to cash flows from operating activities:
Depreciation and amortization	769	697
Stock based compensation expense, net	499	949
Amortization of debt discount and financing fees	0	187
Goodwill and intangibles impairment	3,951	0
Loss on retirement of long-term debt	0	500
Change in fair value of warrant liability	(1,475)	(818)
Warrant valuation expense	67	0
Changes in assets and liabilities:
Accounts receivable	(263)	(282)
Inventory	(911)	(677)
Other current assets	1	342
Other assets and liabilities	0	(464)
Accounts payable and accrued expenses	(1,176)	(934)
Net cash used in operations	(11,920)	(16,292)
Investing activities:
Purchase of property and equipment	(259)	(117)
Purchase of Aquadex product line	0	(4,000)
Net cash used in investing activities	(259)	(4,117)
Financing activities:
Net proceeds from public stock offerings	24,281	0
Net proceeds from exercise of warrants	1,989	0
Net proceeds from the sale of preferred stock, common stock and warrants	184	6,636
Repayments of long-term debt	0	(8,000)
Net cash provided by (used in) financing activities	26,454	(1,364)
Effect of exchange rate changes on cash	(3)	(17)
Net increase (decrease) in cash and cash equivalents	14,272	(21,790)
Cash and cash equivalents - beginning of period	1,323	23,113
Cash and cash equivalents - end of period	15,595	1,323
Supplemental schedule of non-cash activities
Warrants issued as inducement to warrant exercise	509	0
Conversion of temporary equity to permanent equity	485	0
Common stock issued for business acquisition	0	950
Supplemental cash flow information
Interest paid on debt borrowings	0	840
Cash paid for income taxes	$ 6	$ 47

Nature of Business and Significant Accounting Policies

12 Months Ended

Dec. 31, 2017

Nature of Business and Significant Accounting Policies [Abstract]

Nature of Business and Significant Accounting Policies

Note 1—Nature of Business and Significant Accounting Policies

Nature of Business

CHF Solutions, Inc. (the “Company”) is a medical device company focused on commercializing the Aquadex FlexFlow® System for Aquapheresis® therapy. The Aquadex FlexFlow System (Aquadex) is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. CHF Solutions, Inc. is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia, Ireland and Delaware. The Company has been listed on Nasdaq since February 2012.

Prior to July 2016, the Company was focused on developing the C-Pulse® Heart Assist System for treatment of Class III and ambulatory Class IV heart failure. The C-Pulse System utilized the known concept of counterpulsation applied to the aorta. In March 2016, the Company announced that it was no longer enrolling patients into its two clinical studies for the C-Pulse System and that it planned to pursue a new strategic direction. In July 2016, the Company announced that it was moving forward with a therapeutic strategy utilizing neuromodulation rather than counterpulsation. In August 2016, the Company acquired the Aquadex Business from a subsidiary of Baxter International, Inc. (“Baxter”), a global leader in the hospital products and dialysis markets (herein referred to as the “Aquadex Business.”) On September 29, 2016, the Company announced a strategic refocus of its near-term strategy that included halting clinical evaluations of its neuromodulation technology to fully focus its resources on its recently acquired Aquadex Business, taking actions to reduce its cash burn, and reviewing potential strategic alliances and financing alternatives. On May 23, 2017, the Company announced it was changing its name from Sunshine Heart, Inc. to CHF Solutions, Inc. to more appropriately reflect the direction of its business.

During 2017, the Company’s board of directors and stockholders approved two reverse stock splits (together, the Reverse Stock Splits). Neither reverse stock split changed the par value of the Company’s common stock or the number of common or preferred shares authorized by the Company’s Fourth Amended and Restated Certificate of Incorporation. The first reverse stock split was a 1-for-30 reverse split of the Company’s outstanding common stock that became effective after trading on January 12, 2017. The second reverse stock split was a 1-for-20 reverse split of the Company’s outstanding common stock that became effective after trading on October 12, 2017. All share and per-share amounts have been retroactively adjusted to reflect the Reverse Stock Splits for all periods presented.

Going Concern

The Company’s financial statements have been prepared and presented on a basis assuming it continues as a going concern. During the years ended December 31, 2017 and 2016, the Company incurred losses from operations and net cash outflows from operating activities as disclosed in the consolidated statements of operations and cash flows, respectively. At December 31, 2017, the Company had an accumulated deficit of $182.4 million and it expects to incur losses for the foreseeable future. To date, the Company has been funded by debt and equity financings, and although the Company believes that it will be able to successfully fund its operations, there can be no assurance that it will be able to do so or that it will ever operate profitably. These factors raise substantial doubt about the Company’s ability to continue as a going concern through at least twelve months from the report date.

The Company became a revenue generating company after acquiring the Aquadex Business in August 2016. The Company expects to incur additional losses in the near-term as it grows the Aquadex Business, including investments in expanding its sales and marketing capabilities, purchasing inventory, manufacturing components, and complying with the requirements related to being a U.S. public company. To become and remain profitable, the Company must succeed in expanding the adoption and market acceptance of the Aquadex FlexFlow. This will require the Company to succeed in training personnel at hospitals and effectively and efficiently manufacturing, marketing and distributing the Aquadex FlexFlow and related components. There can be no assurance that the Company will succeed in these activities, and it may never generate revenues sufficient to achieve profitability.

On April 24, 2017, the Company closed on an underwritten public equity offering for net proceeds of approximately $8.0 million after deducting the underwriting discounts and commissions and other costs associated with the offering. In addition, on November 27, 2017, the Company closed on a subsequent underwritten public equity offering for net proceeds of approximately $16.2 million after deducting the underwriting discounts and commissions and other costs associated with the offering (see Note 6 - Equity). The Company may require additional funding to grow its Aquadex Business, which may not be available on terms favorable to the Company, or at all. The Company may receive those funds from the proceeds from future warrant exercises, issuances of equity securities, or other financing transactions. Should warrant exercises not materialize or future capital raising be unsuccessful, the Company may not be able to continue as a going concern. No adjustments have been made relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company not continue as a going concern.

Basis of Presentation

The accompanying consolidated financial statements include the accounts of CHF Solutions, Inc. and its wholly owned subsidiaries, CHF Solutions, LLC, Sunshine Heart Company Pty Limited, and Sunshine Heart Ireland Limited. All intercompany accounts and transactions between consolidated entities have been eliminated.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts and disclosures in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and term deposits with original maturities of three months or less. The carrying value of these instruments approximate fair value. The balances, at times, may exceed federally insured limits. The Company has not experienced any losses on its cash and cash equivalents.

Accounts Receivable

Accounts receivable are unsecured, are recorded at net realizable value, and do not bear interest. The Company makes judgments as to its ability to collect outstanding receivables based upon significant patterns of uncollectability, historical experience, and managements’ evaluation of specific accounts and will provide an allowance for credit losses when collection becomes doubtful. The Company performs credit evaluations of its customers’ financial condition on an as-needed basis. Payment is generally due 30 days from the invoice date and accounts past 30 days are individually analyzed for collectability. When all collection efforts have been exhausted, the account is written off against the related allowance. To date the Company has not experienced any write-offs or significant deterioration of its accounts receivable aging, and therefore, no allowance for doubtful accounts was considered necessary as of December 31, 2017 or 2016.

Inventories

Inventories are recorded as the lower of cost or market using the first-in, first out method. Inventories consisted of the following as of December 31 (in thousands):

	2017		2016
Finished Goods	$	902	$	644
Work in Process		217		—
Raw Materials		469		33
Total	$	1,588	$	677

Other Current Assets

Other current assets represent prepayments and deposits made by the Company.

Property, Plant and Equipment

Property and equipment is stated at cost less accumulated depreciation. Depreciation is computed based upon the estimated useful lives of the respective assets. Leasehold improvements and capital lease assets are amortized using the straight-line method over the shorter of the lease term or the estimated useful life of the assets. Repairs and maintenance costs are expensed as incurred. The cost and accumulated depreciation of property, plant and equipment retired, or otherwise disposed of are removed from the related accounts, and any residual values are charged to expense. Depreciation expense has been calculated using the following estimated useful lives:

Office furniture and equipment	5-15 years
Computer software and equipment	3-4 years
Laboratory and research equipment	3-15 years
Production equipment	3-7 years
Leasehold improvements and capital lease asset	3-5 years

Depreciation expense was $229,000 and $419,000 for the years ended December 31, 2017, and 2016, respectively.

Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the impairment tests indicate that the carrying value of the asset, or asset group is greater than the expected undiscounted cash flows to be generated by such asset or asset group further analysis is performed to determine the fair value of the asset or asset group. To the extent the fair value of the asset or asset group is less than its carrying value, an impairment loss is recognized equal to the amount the fair value of the asset or asset group exceeds its carrying amount. The Company generally measures fair value by considering sale prices for similar assets or asset groups, or by discounting estimated future cash flows from such assets or asset groups using an appropriate discount rate. Assets to be disposed of are carried at the lower of their carrying value or fair value less costs to sell. Considerable management judgment is necessary to estimate the fair value of assets or asset groups, and accordingly, actual results could vary significantly from such estimates. The Company reviewed its property and equipment in conjunction with its intangible asset impairment analysis and determined that the fair value of property and equipment equaled or exceeded its carrying value. As a result, there have been no impairment losses recognized for the years ended December 31, 2017 or 2016.

Intangible assets

The Company’s intangible assets consisted of customer relationships, developed technology, and trademarks and tradenames. All intangible assets recognized by the Company resulted from the acquisition of the Aquadex Business. All intangible assets were estimated to have a useful life of 7 years. The Company reviews its definite lived intangible assets for impairment when impairment indicators exist. When impairment indicators exist, the Company determines if the carrying value of the intangible assets exceeds the related undiscounted cash flows. In cases where the carrying value exceeds the undiscounted cash flows, and the carrying amount is not considered recoverable, the carrying value is written down to its fair value, generally using a discounted cash flow analysis. An impairment loss is recognized for the amount that the intangible assets exceeds their fair value, generally based on discounted cash flow methods and other fair market value indicators. The Company’s review of its intangible assets during the year ended December 31, 2017, resulted in $3.8 million of impairment charges related to its finite-lived intangible assets.

The Company has a single reporting unit. The impairment charges were based on fair values determined using market value indicators such as the quoted market prices of the Company’s common stock on Nasdaq, as well discounted cash flow models. Discounted cash flow models include assumptions related to the Company’s product revenue, gross margins, and operating margins, under varying assumptions about the Company’s ability to either achieve profitability or obtain the necessary financings to realize such projections. As discussed above, the Company became a revenue generating company after acquiring the Aquadex Business in August 2016 and expects to incur losses in the near-term as it grows the Aquadex Business. To become and remain profitable, and to generate cash flows from operations, the Company must succeed in expanding the adoption and market acceptance of its products. This will require that the Company succeed in training personnel at hospitals and in effectively and efficiently manufacturing, marketing, and distributing its products. There can be no assurance that the Company will succeed in these activities, and it may never generate revenues sufficient to achieve profitability or positive cash flows. The discounted cash flow models reflect these uncertainties by assigning future cash flow estimations probability factors and an overall discount rate of 30%.

Amortization expense was $540,000 and $278,000 for the years ended December 31, 2017 and 2016, respectively.

Goodwill

Goodwill is the cost of an acquisition in excess of the fair value of acquired assets and liabilities and is recorded as an asset on the balance sheet. Goodwill is not subject to amortization but must be tested for impairment at least annually. This test requires the Company to determine if the implied fair value of the goodwill is less than its carrying amount.

The Company evaluates goodwill for impairment annually on November 1^st of each calendar year, or to the extent events or conditions indicate a risk of possible impairment during the interim periods prior to its annual impairment test. As described below, the Company early adopted Accounting Standards Update No, 2017-04, Simplifying the Test for Goodwill Impairment, and performed a single step in performing its impairment analysis, which is to determine the estimated fair value of its reporting unit and compare it to the carrying value of the reporting unit, including goodwill. The remaining implied goodwill is then compared to the actual carrying amount of the goodwill for the reporting unit. To the extent the carrying amount of goodwill exceeds the implied goodwill, the difference is the amount of the goodwill impairment. The Company’s annual impairment test on November 1, 2018, resulted in $0.2 million of impairment charges related to goodwill.

The Company has a single reporting unit. The impairment charge was based on fair values determined using market value indicators such as the quoted market prices of the Company’s common stock on Nasdaq, as well discounted cash flow models. Discounted cash flow models include assumptions related to the Company’s product revenue, gross margins, and operating margins, under varying assumptions about the Company’s ability to either achieve profitability or obtain the necessary financings to realize such projections. As discussed above, the Company became a revenue generating company after acquiring the Aquadex Business in August 2016 and expects to incur losses in the near-term as it grows the Aquadex Business. To become and remain profitable, and to generate cash flows from operations, the Company must succeed in expanding the adoption and market acceptance of its products. This will require that the Company succeed in training personnel at hospitals and in effectively and efficiently manufacturing, marketing, and distributing its products. There can be no assurance that the Company will succeed in these activities, and it may never generate revenues sufficient to achieve profitability or positive cash flows. The discounted cash flow models reflect these uncertainties by assigning future cash flow estimations probability factors and an overall discount rate of 30%.

Contingent consideration

In connection with the Company’s purchase of the Aquadex Business, the Company has an obligation to pay additional consideration that is contingent upon the occurrence of certain future events. Contingent consideration is recognized at the acquisition date at the estimated fair value of the contingent milestone payments. The fair value of the contingent consideration is remeasured to its estimated fair value at the end of each reporting period, with changes recorded to earnings.

Common stock warrant liability

The Company recorded its common stock warrant liability at fair value at the date of issuance using primarily a Monte Carlo valuation model. The fair value is remeasured to its estimated fair value at the end of each reporting period with changes recorded to earnings.

Revenue Recognition

The Company recognizes revenues from product sales when earned. Specifically, revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured. Revenue is not recognized until title and risk of loss have transferred to the customer. The shipping terms for the Company’s revenue arrangements are generally FOB shipping point.

Foreign Currency Translation

Sales and expenses denominated in foreign currencies are translated at average exchange rates in effect throughout the year. Assets and liabilities of foreign operations are translated at period-end exchange rates with the impacts of foreign currency translation recognized to cumulative translation adjustment, a component of accumulated other comprehensive income. Foreign currency transactions gains and losses are included in other expense, net in the consolidated statements of operations and other comprehensive loss.

Stock-Based Compensation

The Company recognizes all share-based payments to employees and directors, including grants of stock options, restricted stock units (RSUs) and common stock awards in the income statement as an operating expense, based on their fair value. The Company’s stock awards use a graded vesting schedule. The Company recognizes the option expense over the requisite service period, which is generally the vesting period.

The Company computes the estimated fair values of stock options and certain of its warrants using the Black-Scholes option pricing model. The closing market price of the Company’s common stock at the date of grant is used to calculate the fair value of restricted stock units and common stock awards.

Stock-based compensation expense is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

Equity instruments issued to non-employees include RSUs, warrants or options to purchase shares of the Company’s common stock. These RSUs, warrants or options are either fully-vested and exercisable at the date of grant or vest over a certain period during which services are provided. The Company expenses the fair market value of fully vested awards at the time of grant, and of unvested awards over the period in which the related services are received. Unvested awards are remeasured to fair value until they vest.

See Note 7- Stock Based Compensation, for further information regarding the assumptions used to calculate the fair value of share-based compensation.

Income Taxes

Deferred income taxes are provided on a liability method, whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards. Deferred tax liabilities are recognized for taxable temporary differences, which are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (Tax Reform Act) was signed into law making significant changes to the Internal Revenue Code. Changes include a reduction in the corporate tax rates, changes to operating loss carry-forwards and carrybacks, and a repeal of the corporate alternative minimum tax. The legislation reduces the U.S. corporate income tax rates from 34% to 21%. As a result of the enacted law, the Company is required to revalue its deferred tax assets and liabilities at the new enacted rate. The Company re-measured the U.S. deferred income tax assets and liabilities balances using the new enacted tax rate (see Note 9). There was no income tax impact from the remeasurement due to the 100% valuation allowance on the Company’s deferred tax assets.

Loss per share

Basic loss per share is computed based on the net loss for each period divided by the weighted average number of common shares outstanding. The net loss for the year ended December 31, 2017, reflects increases for net deemed dividends to preferred stockholders provided in connection with the close of the public offering of Series E Convertible Preferred Stock in April of 2017, and the close of the public offering of Series F Convertible Preferred Stock in November of 2017, of $1.0 million and $8.7 million, respectively, representing the intrinsic value of the shares at the time of issuance. In addition, the net loss allocable to common stockholders reflects an increase for net deemed dividends of $1.8 million to preferred stockholders provided in connection with the shareholder approval of the Series C and D Convertible Preferred Stock transactions in January of 2017, representing the intrinsic value of the shares at the time of issuance. The net loss allocable to common shareholders for 2016 reflects a $1.9 million increase for the net deemed dividend to preferred shareholders provided in connection with the 2016 Series B and B-1 offering (See Note 5). Diluted earnings per share is computed based on the net loss allocable to common stockholders for each period divided by the weighted average number of common shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued, and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive shares of common stock include warrants, stock options and other stock-based awards granted under stock-based compensation plans.

The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:

	December 31,
	2017		2016
Stock options		36,362		4,354
Restricted stock units		245		499
Warrants to purchase common stock		8,522,684		44,268
Series B, C and D convertible preferred stock		—		53,179
Series F convertible preferred stock		842,940		—-
Total		9,402,231		102,300

The following table reconciles reported net loss with reported net loss per share for the years ended December 31:

(in thousands, except per share amounts)	2017			2016
Net loss	$	(13,382	)	$	(15,792	)
Deemed dividend to preferred shareholders (see Note 6)		(11,590	)		(1,900	)
Net loss after deemed dividend		(24,972	)		(17,692	)
Weighted average shares outstanding		665			33
Basic and diluted loss per share	$	(37.51	)	$	(536.12	)

Research and Development

Research and development costs include activities related to research, development, design, and testing improvements of the Aquadex FlexFlow system and potential related products. Research and development costs also include expenses related to clinical research that the Company may sponsor or conduct to enhance understanding of the product and its use. Research and development expenses are expensed as incurred.

Reclassification

For comparability, certain December 31, 2016 amounts have been reclassified to conform to classifications adopted in December 31, 2017. The reclassifications had no impact on previously reported net loss or equity.

Recent Accounting Pronouncements

In March 2016, the Financial Accounting Standards Board (FASB), issued amended stock compensation guidance to simplify various aspects of employee share-based payments accounting and presentation in the financial statements. The new guidance requires all income tax effects of awards to be recognized in the income statement when the awards vest or are settled, allows an employer to repurchase more of an employee’s shares than previously allowed for tax withholding purposes without triggering liability accounting, allows a company to make a policy election to account for forfeitures as they occur, and eliminates the requirement that excess tax benefits be realized before companies can recognize them. The new guidance also requires excess tax benefits and tax shortfalls to be presented on the cash flow statement as an operating activity rather than as a financing activity, and clarifies that cash paid to a tax authority when shares are withheld to satisfy its statutory income tax withholding obligation are to be presented as a financing activity. The standard was effective for our interim and annual periods beginning after January 1, 2017. The Company adopted the guidance in the current year. The adoption of this standard did not have a material impact to the Company’s consolidated financial statements.

In May 2014, August 2015, March 2016, April 2016 and May 2016, the FASB issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. The standard allows the Company to transition to the new model using either a full or modified retrospective approach, and early adoption is not permitted. The Company has determined that it will use the modified retrospective approach. This guidance will be effective for the Company's interim and annual periods beginning January 1, 2018. As of the end of the fourth quarter of 2017, the Company had nearly completed its assessment of this amended guidance and it does not expect that the adoption of this standard will not have a material impact on the timing and amount of revenue recognized, but it expects to provide expanded disclosures as a result of the adoption. The Company will continue to evaluate the impact of the amended guidance as it pertains to presentation and disclosure.

In November 2015, the FASB issued amended guidance concerning the classification of deferred taxes on the balance sheet to require that deferred tax assets and deferred tax liabilities be presented as noncurrent in a classified balance sheet. The amendment is effective for our annual and interim reporting periods beginning January 1, 2017, with early adoption permitted. The adoption of this standard did not have an impact on the Company’s consolidated financial statements as all deferred tax assets are fully reserved.

In January 2017, the FASB issued amended guidance to simplify the accounting for goodwill impairment by removing Step 2 of the goodwill impairment test. A goodwill impairment will now be measured as the amount by which a reporting unit’s carrying value exceeds its fair value, limited to the amount of goodwill allocated to that reporting unit. This guidance is to be applied on a prospective basis effective for the Company’s interim and annual periods beginning after January 1, 2019, with early adoption permitted for any impairment tests performed after January 1, 2017. The Company adopted this amended guidance in the current year, as further described above under Significant Accounting Policies.

In February 2016, the FASB issued updated guidance to improve financial reporting about leasing transactions. This guidance will require organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. This guidance is effective for the Company’s annual reporting period ending December 31, 2020, and for annual and interim periods thereafter. The Company is evaluating the impact that the adoption of this standard will have, if any, on its financial statements and disclosures.

The Company evaluates events through the date the consolidated financial statements are filed for events requiring adjustment to or disclosure in the consolidated financial statements.

Aquadex Acquisition

12 Months Ended

Dec. 31, 2017

Aquadex Acquisition [Abstract]

Aquadex Acquisition

Note 2 – Aquadex Acquisition

On August 5, 2016, the Company completed the acquisition of certain assets used in the production and sale of the Aquadex product line from Baxter. The acquisition of these assets meets the criteria for the purchase of a business and has been accounted for in accordance with Accounting Standards Codification (ASC) 805, Business Combinations, with identifiable assets acquired and liabilities assumed recorded at their estimated fair values on the acquisition date. A valuation of the assets and liabilities from the business acquisition was performed utilizing cost, income and market approaches resulting in $5.1 million allocated to identifiable net assets.

In connection with the acquisition of the Aquadex Business, the Company entered into a manufacturing and supply agreement with Baxter whereby Baxter agreed to manufacture and supply all of the Company’s finished goods for a period of up to 18 months from the close of the transaction. During the years ended December 31, 2017 and 2016, the Company recorded $3.6 and $1.2 million of revenue from the sale of Aquadex products. The Company completed the acquisition in order to strengthen its presence in the heart failure market.

Purchase Consideration: Total purchase consideration for the Aquadex Business was as follows:

(in thousands)
Cash consideration	$	4,000
Common stock consideration		950
Fair value of contingent consideration		126
Total purchase consideration	$	5,076

Common Stock Consideration: The common stock consideration consisted of 1,666 shares of the Company’s common stock, worth $0.95 million based on the closing market value of $570 per share on August 5, 2016.

Contingent Consideration: In connection with the acquisition of the Aquadex product line, the Company agreed to pay the Seller 40% of any proceeds in excess of $4.0 million related to the sale or disposal of the Aquadex assets within three years of the close of the transaction. The fair value of this contingent consideration was calculated based on the estimated likelihood of occurrence of this event in the timeframe provided by the agreement.

Purchase price consideration does not include expenses of $0.9 million for accounting, audit, legal, and valuation services that were incurred as part of the transaction and were expensed as incurred as general and administrative expense in the accompanying consolidated statement of operations.

The acquisition was recorded by recognizing the assets acquired at their estimated fair value at the acquisition date. The excess of the cost of the acquisition over the fair value of the assets acquired was recorded as goodwill. The fair values were based on management’s analysis, including work performed by third-party valuation specialists. The following presents the amounts recognized for the assets acquired on August 5, 2016 (in thousands):

Capital lease asset	$	307
Intangible assets		4,580
Total identifiable assets acquired		4,887
Goodwill		189
Total purchase consideration	$	5,076

The goodwill is primarily attributable to new and/or future customer relationships that were not acquired in the transaction. All recorded goodwill is expected to be deductible for tax purposes. The fair value of the capital lease asset utilized a combination of the cost and market approaches, depending on the characteristics of the asset classification.

Pro Forma Condensed Combined Financial Information (Unaudited)

The following unaudited pro forma combined financial information summarizes the results of operations for the periods indicated as if the acquisition of Aquadex had been completed on of January 1, 2016. Pro forma information reflects adjustments that are expected to have a continuing impact on our results of operations and are directly attributable to the acquisition. The unaudited pro forma results include adjustments to reflect, among other things, direct transaction costs relating to the acquisition, the difference in intangible asset amortization to be incurred based on the preliminary values of each identifiable intangible asset, and the difference in depreciation expense to be incurred based on preliminary value of the capital lease asset. The pro forma amounts do not purport to be indicative of the results that would have actually been obtained if the acquisition had occurred as of January 1, 2016 or that may be obtained in the future, and do not reflect future synergies, integration costs, or other such costs or savings.

Twelve months ended December 31, 2016 (in thousands, except share amounts)
Pro forma net sales	$	3,160
Pro forma net loss from operations		(15,340	)
Pro forma basic and diluted net loss per share	$	(464.84	)

Property, Plant and Equipment

12 Months Ended

Dec. 31, 2017

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

Note 3—Property, Plant and Equipment

Property, plant and equipment were as follows:

(in thousands)	December 31, 2017			December 31, 2016
Office Furniture & Fixtures	$	287		$	280
Leasehold Improvements		224			145
Software		129			124
Production Equipment		926			968
Computer Equipment		277			245
Capital Lease Asset		307			307
Total		2,150			2,069
Accumulated Depreciation		(1,580	)		(1,529	)
	$	570		$	540

Intangible Assets

12 Months Ended

Dec. 31, 2017

Intangible Assets [Abstract]

Intangible Assets

Note 4—Intangible Assets

Intangible assets were as follows:

(in thousands)	December 31, 2017			December 31, 2016
Customer Relationships	$	3,090		$	3,090
Developed Technology		1,050			1,050
Trade Names and Trademarks		440			440
Total		4,580			4,580
Accumulated Amortization		(818	)		(278	)
Impairment Charge		(3,762	)		—
	$	—		$	4,302

The Company’s review of its intangible assets during the year ended December 31, 2017, resulted in $3.8 million of impairment charges related to its finite-lived intangible assets. The impairment charges were based on fair values determined using market value indicators such as the quoted market prices of the Company’s common stock on Nasdaq, as well discounted cash flow models. Discounted cash flow models include assumptions related to the Company’s product revenue, gross margins, and operating margins, under varying assumptions about the Company’s ability to either achieve profitability or obtain the necessary financings to realize such projections. As discussed in Note 1, the Company became a revenue generating company after acquiring the Aquadex Business in August 2016 and expects to incur losses in the near-term as it grows the Aquadex Business. To become and remain profitable, and to generate cash flows from operations, the Company must succeed in expanding the adoption and market acceptance of its products. This will require that the Company succeed in training personnel at hospitals and in effectively and efficiently manufacturing, marketing, and distributing its products. There can be no assurance that the Company will succeed in these activities, and it may never generate revenues sufficient to achieve profitability or positive cash flows. The discounted cash flow models reflect these uncertainties by assigning future cash flow estimations probability factors and an overall discount rate of 30%.

Debt	12 Months Ended
Debt	Dec. 31, 2017
Debt [Abstract]
Debt	Note 5—Debt Prior Loan Agreement: On February 18, 2015, the Company entered into a loan and security agreement with Silicon Valley Bank (the Bank) for proceeds of up to $10.0 million at an annual interest rate of 7.0%. Under this agreement, a $6.0 million term loan was funded at closing and an additional term loan in the amount of $2.0 million was funded on June 26, 2015. The proceeds from the term loans were used for general corporate and working capital purposes. Commencing on January 1, 2016, the Company began repaying the advances made in twenty-four consecutive equal monthly installments. On August 4, 2016, the Company repaid all amounts outstanding under its existing debt facility of $5.5 million and incurred a $0.5 million loss on early extinguishment of debt, including the accelerated write-off of unamortized warrants and debt issuance costs. There were no borrowings outstanding under this facility as of December 31, 2017 or 2016. Warrants: In connection with the funding of these term loans, the Company issued 115 warrants at an exercise price of $3,132 per share and 55 warrants at an exercise price of $2,208 per share to the Bank and one of its affiliates. The Company valued these warrants at $2,316 per share and $1,626 per share, respectively, utilizing the Black Scholes option pricing model and the following assumptions: an expected dividend yield of 0%, an expected stock price volatility of 88.07% and 87.04%, a risk-free interest rate of 1.86% and 2.20%, and an expected life of 6.25 years. The warrants have a life of ten years and were fully vested at the date of grant. New Loan Agreement: On August 5, 2016, the Company entered into a new loan and security agreement with the Bank (the “New Loan Agreement”). Under the New Loan Agreement, the Bank agreed to provide the Company with up to $5.0 million in debt financing, consisting of a term loan in an aggregate original principal amount not to exceed $4.0 million (the “Term Loan”) and a revolving line of credit in an aggregate principal amount not to exceed $1.0 million outstanding at any time (the “Revolving Line”; together with the Term Loan, the “Loans”). Proceeds from the Loans were to be used for general corporate and working capital purposes. Advances under the Term Loan were available to the Company until November 30, 2016 and were subject to the Company’s compliance with liquidity covenants. The Term Loan expired unused on November 30, 2016. Advances under the Revolving Line are available to the Company until March 31, 2020 and accrue interest at a floating annual rate equal to 1.75% or 1.0% above the prime rate, depending on liquidity factors. Outstanding borrowings, if any, are collateralized by all of the Company’s assets, excluding intellectual property which is subject to a negative pledge. There were no borrowings outstanding under this facility as of December 31, 2017 or 2016.

Shareholder's Equity	12 Months Ended
Shareholder's Equity	Dec. 31, 2017
Shareholder's Equity [Abstract]
Shareholder's Equity	Note 6—Shareholder’s Equity Series B/B-1 Convertible Preferred Stock: On July 20, 2016, the Company entered into a securities purchase agreement with an institutional investor for an offering of shares of convertible preferred stock and warrants with gross proceeds of approximately $3.5 million in a registered direct offering. The transaction closed on July 26, 2016, and the Company issued 3,468 shares of Series B Convertible Preferred Stock. The Series B Convertible Preferred Stock is non-voting and was convertible into a total of 6,149 shares of common stock at the holder’s election at any time at a conversion price of $564.0 per share. Approximately $1.6 million of the proceeds were allocated to the preferred stock, representing the residual proceeds after the warrants (described below) were recorded at fair value. On October 30, 2016, the Company entered into an exchange agreement with the holders of its Series B Convertible Preferred Stock and agreed to issue such holders 2,227.2 shares of the Company’s Series B-1 Convertible Preferred Stock in exchange for the cancellation of all shares of Series B Convertible Preferred Stock held by such holders. The Series B-1 Convertible Preferred Stock had similar terms as the Series B Convertible Preferred Stock, except that the initial conversion price of the Series B-1 Convertible Preferred Stock was $102 per share. As of December 31, 2016, 402.8 shares of the Series B-1 Convertible Preferred Stock had been converted into 3,948 shares of common stock, and 1,824.4 shares of Series B-1 Convertible Preferred Stock remained outstanding. As of December 31, 2017, all remaining Series B-1 Convertible Preferred Stock had been converted into an additional 17,866 shares of common stock and none remained outstanding. The Series B and B-1 convertible preferred stock include a net deemed dividend in the amount of $1.9 million, representing the intrinsic value of the shares at the time of issuance, which is reflected as an increase to the loss per share allocable to common shareholders. Series C and D Convertible Preferred Stock: Also, on October 30, 2016, the Company entered into a securities purchase agreement with an institutional investor for shares of convertible preferred stock and warrants with an aggregate purchase price of $3.8 million in a registered direct offering and simultaneous private placement. The first closing of the transaction occurred on November 3, 2016, whereby the Company received $3.6 million in gross proceeds and issued and sold 2,900 shares of Series C Convertible Preferred Stock, and 700 shares of Series D Convertible Preferred Stock, both with conversion prices of $102 per share. At the second closing, on January 10, 2017, the Company issued and sold 200 shares of Series D Convertible Preferred Stock with a conversion price of $102 per share for gross proceeds of $0.2 million. The Series C and D Convertible Preferred Stock included a contingent beneficial conversion amount of $1.3 million and $0.5 million, respectively, representing the intrinsic value of the shares at the time of issuance. This amount is reflected as an increase to the loss per share allocable to common stockholders in the first quarter of 2017 when the contingency for the conversion was resolved with the shareholder approval allowing for the conversion of the preferred stock into common stock. As of December 31, 2016, 2,900 shares of Series C Convertible Preferred Stock and 700 shares of Series D Convertible Preferred Stock were outstanding, and none had been converted. As of December 31, 2017, all shares of the Series C and D Convertible Preferred Stock had been converted into an aggregate of 55,712 shares of common stock and none remained outstanding. The Series D Convertible Preferred Stock with a carrying value of $0.5 million was classified as temporary equity in the consolidated balance sheet as of December 31, 2016 because the Company could not control the settlement of its redemption in common stock. The temporary equity was not remeasured to fair value each period through earnings because the events that could trigger its redemption were not probable of occurrence. There were no shares of the Series D Convertible Preferred Stock outstanding as of December 31, 2017. Series E Convertible Preferred Stock: On April 24, 2017, the Company closed on an underwritten public offering of common stock, Series E Convertible Preferred Stock and warrants to purchase shares of common stock for gross proceeds of $9.2 million, which included the full exercise of the underwriter’s over-allotment option to purchase additional shares and warrants. Net proceeds totaled approximately $8.0 million after deducting the underwriting discounts and commissions and other costs associated with the offering. The offering comprised of Class A Units, priced at a public offering price of $20.00 per unit, with each unit consisting of one share of common stock and one five-year warrant to purchase one share of common stock with an exercise price of $22 per share, and Class B Units, priced at a public offering price of $1,000 per unit, with each unit comprised of one share of preferred stock, which was convertible into 50 shares of common stock, and warrants to purchase 50 shares of common stock, also with an exercise price of $22 per share. The conversion price of the Series E Convertible Preferred Stock as well as the exercise price of the warrants are fixed and do not contain any variable pricing features nor any price based anti-dilutive features apart from customary adjustments for splits and reverse splits of common stock. A total of 140,000 shares of common stock, 6,400 shares of Series E Convertible Preferred Stock convertible into 320,000 shares of common stock and warrants to purchase 640,000 shares of common stock were issued in the offering including the full exercise of the underwriter’s over-allotment option to purchase additional shares and warrants. The Series E Convertible Preferred Stock included a beneficial conversion amount of $1.0 million, representing the intrinsic value of the shares at the time of issuance. This amount is reflected as an increase to the loss per share allocable to common stockholders in the year ended December 31, 2017. As of December 31, 2017, all shares of the Series E Convertible Preferred Stock had been converted into an aggregate of 320,000 shares of common stock and none remained outstanding. Series F Convertible Preferred Stock: On November 27, 2017, the Company closed on an underwritten public offering Series F Convertible Preferred Stock and warrants to purchase shares of common stock for gross proceeds of $18.0 million. Net proceeds totaled approximately $16.2 million after deducting the underwriting discounts and commissions and other costs associated with the offering. The offering was comprised of Series F preferred stock, convertible into shares of the Company’s common stock at a conversion price of $4.50 per share. Each share of Series F preferred stock was accompanied by a Series 1 warrant, which expires on the first anniversary of its issuance, to purchase 223 shares of the Company’s common stock at an exercise price of $4.50 per share, and a Series 2 warrant, which expires on the seventh anniversary of its issuance, to purchase 223 shares of the Company’s common stock at an exercise price of $4.50 per share. The Series F preferred stock and the warrants were immediately separable and were issued separately. The conversion price of the Series F Convertible Preferred Stock as well as the exercise price of the warrants are fixed and do not contain any variable pricing features, nor any price based anti-dilutive features apart from customary adjustments for splits and reverse splits of common stock. A total of 18,000 shares of Series F Convertible Preferred Stock convertible into approximately 4.0 million shares of common stock and warrants to purchase approximately 8.0 million shares of common stock were issued in the offering. The Series F Convertible Preferred Stock included a beneficial conversion amount of $8.7 million, representing the intrinsic value of the shares at the time of issuance. This amount is reflected as an increase to the loss per share allocable to common stockholders in the year ended December 31, 2017. As of December 31, 2017, 14,220 shares of the Series F Convertible Preferred Stock had been converted into an aggregate of 3,171,060 shares of common stock and 3,780 remained outstanding. In connection with the issuance of the Series B, C and D Convertible Preferred Shares, the Company paid the placement agent an aggregate cash placement fee equal to 6% of the aggregate gross proceeds raised in the offering and issued warrants as described below. In connection with the issuance of the Series E and F Convertible Preferred Shares, the Company paid the placement agent an aggregate cash placement fee equal to 9% and 8%, respectively, of the aggregate gross proceeds raised in the offering and issued no warrants to the placement agent. Investor Warrants: In connection with the issuance of the Series B Convertible Preferred Stock in July 2016, the Company issued the investor at no additional cost warrants to purchase 6,149 shares of common stock at an exercise price of $564 per share. The warrants were exercisable for 36 months commencing six months from the closing date and were subject to a reduction of the exercise price if the Company subsequently issued common stock or equivalents at an effective price less than the current exercise price of such warrants. Concurrently with the closing of the Series C and D Convertible Preferred Stock and warrant financing on November 3, 2016, the exercise price for these warrants was adjusted to $102 per share. In connection with the issuance of the Series C and D Convertible Preferred Stock in November 2016, the Company issued the investor at no additional cost warrants to purchase 35,295 shares of common stock at an exercise price of $108 per share. In connection with the issuance of the Series D Convertible Preferred Stock at the second closing in January 2017, the Company issued the investor at no additional cost warrants to purchase 1,961 shares of common stock at an exercise price of $108 per share. The warrants were exercisable for 60 months commencing on the earlier of the day of the receipt of approval of the Company’s stockholders of a proposal to approve the issuance of the shares of common stock underlying the warrants, or the six-month anniversary of the date of issuance. These warrants were subject to a reduction of the exercise price if the Company subsequently issued common stock or equivalents at an effective price less than the current exercise price of such warrants. Warrant Exercise Agreement: On February 15, 2017, the Company entered into a letter agreement with the institutional investors that held the majority of its outstanding warrants (the “Original Warrants”), to incent the cash exercise of these warrants on or before March 31, 2017. In exchange for any such exercise, the Company agreed to provide the investors a replacement warrant (the “Replacement Warrants”) to purchase the same number of shares of common stock as were issued upon exercise of the Original Warrants, with an exercise price equal to the consolidated closing bid price of its common stock on the date of issuance. The Replacement Warrants were issued in the same form as the Original Warrants except the exercise prices are not subject to reduction for subsequent equity issuances and the Replacement Warrants do not allow the investor to demand that the Company purchase the Replacement Warrants in the event of a fundamental transaction involving the Company. In connection with this agreement, between February and March 2017, the investors exercised all of the Original Warrants for gross cash proceeds to the Company of $2.0 million, and the Company issued 43,396 Replacement Warrants with exercise prices ranging from $34.6 per share to $99.8 per share. The Company entered into the letter agreement with the investors to incent the exercise of the Original Warrants in order to receive the cash proceeds from the exercise of the Original Warrants and because the exercise of the Original Warrants would allow the Company to remove the warrant liability from its balance sheet and avoid future fair value adjustments and associated volatility in its consolidated financial statements, as the Replacement Warrants are not accounted for as liabilities based on their terms. As of December 31, 2017, there were no Original Warrants outstanding and all Replacement Warrants under the letter agreement had been issued. Warrant Valuation: Both the Original Warrants and placement agent warrants were accounted for as liabilities and were recorded at fair value on the date of issuance. These warrants must be measured and recorded at fair value for each subsequent reporting period that the warrants remain outstanding, and any changes in fair value must be recognized in the consolidated statement of operations. In connection with the warrant exchange agreement described above, the Company remeasured each Original Warrant as of the date of exercise and recorded $1.5 million for the change in fair value of these warrants as an unrealized gain in the accompanying consolidated statement of operations for year ended December 31, 2017. The warrant liability totaled $1.8 million as of December 31, 2016 and $0 as of December 31, 2017. The Replacement Warrants were valued at $0.5 million using the Black Scholes option pricing model with the following assumptions: an expected dividend yield of 0%, expected stock price volatility of 49.65%-50.38%, risk-free interest rates of 1.95%-1.97% and an expected life of 5 years. The warrants have a five-year life and were fully vested at the date of grant. The terms of the Replacement Warrants do not require them to be accounted for as liabilities and are therefore recorded in equity. As in incentive to early exercise the Original Warrants, the fair value provided to investors through the Replacement Warrants exceeded the fair value of the Original Warrants that was relinquished by the warrant holders by approximately $0.1 million, which has been reflected as an expense in the consolidated statement of operations for the year ended December 31, 2017.

Stock-Based Compensation

12 Months Ended

Dec. 31, 2017

Stock-Based Compensation [Abstract]

Stock-Based Compensation

Note 7— Stock-Based Compensation

Stock Options and Restricted Stock Awards

The Company has various share-based compensation plans, including the Amended and Restated 2002 Stock Plan, the Third Amended and Restated 2017 Equity Incentive Plan, the 2013 Non-Employee Directors’ Equity Incentive Plan and the New-Hire Equity Incentive Plan (collectively, the “Plans”). The Plans are designed to assist in attracting, motivating and retaining employees and directors and to recognize the importance of employees to the long-term performance and success of the Company. The Company has also granted stock options to certain non-employees outside of the Plans.

The Company recognized share-based compensation expense related to grants of stock options, RSUs and common stock awards to employees, directors and consultants of $0.5 million, and $1.0 million during the years ended December 31, 2017 and 2016, respectively. The following table summarizes the stock-based compensation expense which was recognized in the consolidated statements of operations for the years ended December 31,

(Dollars in thousands)	2017		2016
Selling, general and administrative	$	452	$	630
Research and development		50		385
Total	$	502	$	1,015

The majority of the RSUs and options to purchase common stock vest on the anniversary of the date of grant, which ranges from one to four years. Share-based compensation expense related to these awards is recognized on a straight-line basis over the related vesting term in most cases, which generally is the service period. It is the Company’s policy to issue new shares upon the exercise of options.

Stock Options: The following is a summary of the Plans’ stock option activity during the years ended December 31:

	2017					2016
	Options Outstanding			Weighted Average Exercise Price		Options Outstanding			Weighted Average Exercise Price
Beginning Balance		4,354		$	2,295.37		3,260		$	3,664.61
Granted		34,651		$	11.57		2,257		$	543.63
Exercised		—			—		—			—
Forfeited/expired		(2,643	)	$	2,666.48		(1,163	)	$	2,729.60
Outstanding at December 31		36,362		$	91.48		4,354		$	2,295.37
Vested at December 31		2,344		$	964.27		2,134		$	3,780.79

For options outstanding and vested at December 31, 2017, the weighted average remaining contractual life was 9.33 years and 8.29 years, respectively. There were no option exercises in 2017 or 2016. The total fair value of options that vested in 2017 and 2016 was $0.7 million, and $1.1 million, respectively, at the fair value of the options as of the date of grant.

Valuation Assumptions: The fair value of each stock option is estimated at the grant date using the Black-Scholes option pricing model. The fair value of stock options under the Black-Scholes option pricing model requires management to make assumptions regarding projected employee stock option exercise behaviors, risk-free interest rates, volatility of the Company’s stock price, and expected dividends.

The Company has not historically paid cash dividends to its stockholders, and currently does not anticipate paying any cash dividends in the foreseeable future. As a result, the Company has assumed a dividend yield of 0%. The risk-free interest rate is based upon the rates of U.S. Treasury bills with a term that approximates the expected life of the option. Since the Company has limited historical exercise data to reasonably estimate the expected life of its option awards, the expected life is calculated using a simplified method. Expected volatility is based on historical volatility of the Company’s stock.

The following table provides the weighed average assumptions used in the Black-Scholes option pricing model for the years ended December 31:

	2017			2016
Expected dividend yield		0	%		0	%
Risk-free interest rate		1.97	%		1.71	%
Expected volatility		103	%		86	%
Expected life (in years)		6.25			6.25

The weighted-average fair value of stock options granted in 2017 and 2016 was $11.97 and $543.63, respectively. As of December 31, 2017, the total compensation cost related to all non-vested stock option awards not yet recognized was approximately $744,000 and is expected to be recognized over the remaining weighted-average period of 3.1 years.

Restricted Stock Awards: The following table summarizes restricted stock award activity during 2017 and 2016:

	2017					2016
	RSUs			Weighted Average Grant Price		RSUs			Weighted Average Grant Price
Nonvested, beginning balance		499		$	583.29		15		$	2,574.00
Granted		138		$	108.20		1,131		$	553.88
Vested		(392	)	$	132.70		(619	)	$	443.40
Forfeited		—			—		(28	)	$	426.00
Nonvested at December 31		245		$	521.23		499		$	583.29

During 2017, and 2016, employees tendered restricted stock units totaling 15, and 165, respectively, to cover related payroll tax withholdings.

Warrants

Warrants to purchase 8,522,684, and 44,268 shares of common stock were outstanding at December 31, 2017 and 2016, respectively. As of December 31, 2017, warrants outstanding were exercisable at prices ranging from $4.50 to $383.57 per share, and are exercisable over a period ranging from eleven months to 7.5 years.

Fair Value of Financial Instruments

12 Months Ended

Dec. 31, 2017

Fair Value of Financial Instruments [Abstract]

Fair Value of Financial Instruments

Note 8 - Fair Value of Financial Instruments

The Company’s financial instruments consist of cash and cash equivalents, warrants, and contingent consideration.

Pursuant to the requirements of ASC Topic 820 “Fair Value Measurement,” the Company’s financial assets and liabilities measured at fair value on a recurring basis are classified and disclosed in one of the following three categories:

•

Level 1 - Financial instruments with unadjusted quoted prices listed on active market exchanges.

•

Level 2 - Financial instruments lacking unadjusted, quoted prices from active market exchanges, including over the counter traded financial instruments. The prices for the financial instruments are determined using prices for recently traded financial instruments with similar underlying terms as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.

•

Level 3 - Financial instruments that are not actively traded on a market exchange. This category includes situations where there is little, if any, market activity for the financial instrument. The prices are determined using significant unobservable inputs or valuation techniques.

The fair value of the Company’s common stock warrant liability related to the investor warrants was calculated using a Monte Carlo valuation model and was classified as Level 3 in the fair value hierarchy. The fair value of the Company’s common stock warrant liability related to the placement agent warrants is calculated using a Black Scholes option pricing model and is classified as Level 3 in the fair value hierarchy.

The following is a rollfoward of the fair value of Level 3 warrants:

(in thousands)
July 26, 2016 warrant issuance	$	1,883
November 3, 2016 warrant issuance		778
Change in fair value		(818	)
Ending balance December 31, 2016		1,843
Change in fair value		(1,475	)
Exercise of warrants		(368	)
Ending balance as of December 31, 2017	$	—

Fair values were calculated using the following assumptions:

	July 26, 2016			Nov. 3, 2016			Dec. 31, 2016
Risk-free interest rates, adjusted for continuous compounding		0.94	%		1.33	%		1.47/1.96	%
Term (years)		3.5			5.5			3.1/5.3
Expected volatility		78	%		41.4	%		55.3/49.8	%
Dates and probability of future equity raises		various			various			various

A significant change in the inputs used for the Monte Carlo and Black Scholes option pricing models such as the expected volatility, bond yield of equivalent securities, or probability of future equity financings, in isolation, would result in significantly higher or lower fair value measurements. In combination, changes in these inputs could result in a significantly higher or lower fair value measurement if the input changes were to be aligned or could result in a minimally higher or lower fair value measurement if the input changes were of a compensating nature.

The fair value of the Company’s contingent consideration, as described in Note 2, was initially measured based on the consideration expected to be transferred (probability-weighted), discounted back to present value, and it is considered a Level 3 instrument. The discount rate used was determined at the time of measurement in accordance with accepted valuation methods. The Company measures the liability on a recurring basis using Level 3 inputs including probabilities of payment and projected payment dates. Changes to any of the inputs may result in significantly higher or lower fair value measurements. There were no changes in the fair value of the contingent consideration subsequent to the initial measurement.

All cash equivalents are considered Level 1 measurements for all periods presented. The Company does not have any financial instruments classified as Level 2 or any other classified as Level 3 and there were no movements between these categories during the periods ended December 31, 2017 and 2016. The Company believes that the carrying amounts of all remaining financial instruments approximate their fair value due to their relatively short maturities.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Income Taxes

12 Months Ended

Dec. 31, 2017

Income Taxes [Abstract]

Income Taxes

Note 9—Income Taxes

Domestic and foreign loss before income taxes, consists of the following for the years ended December 31:

(in thousands)	2017			2016
Domestic	$	(13,367	)	$	(15,877	)
Foreign		(9	)		31
Loss before income taxes	$	(13,376	)	$	(15,846	)

The components of income tax benefit (expense) consist of the following for the years ended December 31:

(in thousands)	2017			2016
Current:
United States and state	$	—		$	—
Foreign, net		(6	)		54
Deferred:
United States and state		—			—
Foreign		—			—
Total income tax benefit (expense)	$	(6	)	$	54

Actual income tax benefit (expense) differs from statutory federal income tax benefit (expense) as follows for the years ended December 31:

(in thousands)	2017			2016
Statutory federal income tax benefit	$	4,548		$	5,388
State tax benefit, net of federal taxes		48			2
Foreign tax		—			3
R&D tax credit		—			80
Foreign deferred exchange rate adjustments		899			—
Nondeductible/nontaxable items		(114	)		(86	)
New federal rate adjustment		(16,081	)		—
Other		(1,085	)		(257	)
Valuation allowance decrease (increase)		11,779			(5,076	)
Total income tax benefit (expense)	$	(6	)	$	54

Deferred taxes consist of the following as of December 31:

(in thousands)	2017			2016
Deferred tax assets:
Noncurrent:
Accrued leave	$	32		$	43
Other accrued expenses		28			97
Stock based compensation		336			1,477
Net operating loss carryforward		38,947			49,720
Deferred rent		7			17
Other		108			777
Intangibles		895
R&D credit carryforward		531			531
Total deferred tax assets	$	40,884		$	52,662
Less: valuation allowance		(40,884	)		(52,662	)
Total	$	—		$	—

On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (Tax Reform Act) was signed into law making significant changes to the Internal Revenue Code. Changes include a reduction in the corporate tax rates, changes to operating loss carry-forwards and carrybacks, and a repeal of the corporate alternative minimum tax. The legislation reduces the U.S. corporate income tax rates from 34% to 21%. As a result of the enacted law, the Company is required to revalue its deferred tax assets and liabilities at the new enacted rate. The Company re-measured the U.S. deferred income tax assets and liabilities balances using the new enacted tax rate. There was no income tax impact from the re-measurement due to the 100% valuation allowance on the Company’s deferred tax assets.

As of December 31, 2017, the Company had net operating loss (“NOLs”) carryforwards of approximately $120.2 million for U.S. federal income tax purposes, which expire between 2024 and 2037, and NOLs in the

Commonwealth of Australia of approximately AU$49.0 million which the Company can carry forward indefinitely. U.S. NOLs cannot be used to offset taxable income in foreign jurisdictions. In addition, future utilization of NOL carryforwards in the U.S. may be subject to certain limitations under Section 382 of the Internal Revenue Code.

The Company received $80,000 fully refundable research and development tax credits in 2016, related to qualified research and development expenditures of its Australian subsidiary for its tax years ended June 30, 2015, and recorded the benefit in the year that the refund was received. The Company received no refunds in 2017 as it has ceased its research and development activities in Australia.

The Company provides for a valuation allowance when it is more likely than not that it will not realize a portion of the deferred tax assets. The Company has established a valuation allowance for U.S. and foreign deferred tax assets due to the uncertainty that enough taxable income will be generated in those taxing jurisdictions to utilize the assets. Therefore, the Company has not reflected any benefit of such deferred tax assets in the accompanying financial statements. For the year ended December 31, 2017, the valuation allowance decreased by $11.8 million primarily as result of the impact of the tax reform re-measurement of deferred tax assets. For the year ended December 31, 2016 the valuation allowance increased by $5.8 million primarily due to current year operating losses. During 2017, the Company experienced an ownership change as defined in Section 382 of the Internal Revenue Code which will limit the ability to utilize the Company’s net operating losses (NOLs). The Company may have experienced additional ownership changes in earlier years further limiting the NOL carry-forwards that may be utilized. The Company has not yet completed a formal Section 382 analysis. The general limitation rules allow the Company to utilize its NOLs subject to an annual limitation that is determined by multiplying the federal long-term tax-exempt rate by the Company’s value immediately before the ownership change.

The accounting guidance related to uncertain tax positions prescribes a recognition threshold and measurement attribute for recognition and measurement of a tax position taken or expected to be taken in a tax return. It also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company had no material uncertain tax positions as of December 31, 2017 or 2016.

The Company recognizes interest and penalties on unrecognized tax benefits as well as interest received from favorable tax settlements within income tax expense. At December 31, 2017 and 2016, the Company recorded no accrued interest or penalties related to uncertain tax positions.

The tax years ended December 31, 2014 through December 31, 2017 remain open to examination by the Internal Revenue Service and for the various states where we are subject to taxation. Additionally, the returns of the Company’s Australian and Irish subsidiary are subject to examination by tax authorities of those jurisdictions for the tax years ended and subsequent to June 30, 2013 and December 31, 2014, respectively.

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2017
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 10—Commitments and Contingencies Leases The Company leases office space under a non-cancelable operating lease that expires in March 2019. The lease contains provisions for future annual inflationary adjustments. Rent expense is recognized using the straight-line method over the term of the lease. The Company leases office equipment under non-cancelable operating leases that expire at various times through February 2019. Rent expense related to operating leases was approximately $290,000, and $286,000 for the years ended December 31, 2017 and 2016, respectively. Future minimum lease payments under non-cancelable operating leases as of December 31, 2017, were approximately $212,000, $60,000, $7,000, $0, and $0 for each of the years ended December 31, 2018, through 2022, respectively. Employee Retirement Plan The Company has a 401(k) profit sharing plan that provides retirement benefit to substantially all full-time U.S. employees. Eligible employees may contribute a percentage of their annual compensation, subject to Internal Revenue Service limitations, with the Company matching a portion of the employee’s contributions at the discretion of the Company. Matching contributions totaled $138,000 and $122,000 for the years ended December 31, 2017 and 2016, respectively. Inventory Purchase Commitments In connection with the acquisition of the Aquadex Business, the Company entered into a manufacturing and supply agreement with Baxter that was to expire within a period not to exceed 18 months from the close of the transaction. In May 2017, the Company notified Baxter to cease the manufacturing of the Aquadex product line as of June 30, 2017. In connection with this notification, the Company agreed to purchase the remaining Aquadex inventory, which consists mainly of raw materials priced at cost, through February 2018, for a total of $2.4 million. As of December 31, 2017, the Company had purchased and paid $1.2 million of this inventory and $1.2 million remained to be purchased. Contingent Consideration As described on Note 2, the Company agreed that if it disposes of any of the Aquadex assets for a price that exceeds $4.0 million within three years of the closing, it will pay Baxter 40% of the amount of such excess. In addition, it also agreed that if shares of its common stock cease to be publicly traded on Nasdaq, Baxter has the option to require the Company to repurchase, in cash, all or any part of the common shares held by Baxter at a price equal to their fair market value, as determined by a third-party appraiser.

Segment and Geographic Information	12 Months Ended
Segment and Geographic Information	Dec. 31, 2017
Segment and Geographic Information [Abstract]
Segment and Geographic Information	Note 11—Segment and Geographic Information The Company has one reportable segment, cardiac and coronary disease products. At December 31, 2017, long-lived assets were located primarily in the United States.

Nature of Business and Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2017

Nature of Business and Significant Accounting Policies [Abstract]

Going Concern

Basis of Presentation

Use of Estimates

Cash and Cash Equivalents

Accounts Receivable

Inventories

Inventories are recorded as the lower of cost or market using the first-in, first out method. Inventories consisted of the following as of December 31 (in thousands):

	2017		2016
Finished Goods	$	902	$	644
Work in Process		217		—
Raw Materials		469		33
Total	$	1,588	$	677

Other Current Assets

Other current assets represent prepayments and deposits made by the Company.

Property, Plant and Equipment

Office furniture and equipment	5-15 years
Computer software and equipment	3-4 years
Laboratory and research equipment	3-15 years
Production equipment	3-7 years
Leasehold improvements and capital lease asset	3-5 years

Depreciation expense was $229,000 and $419,000 for the years ended December 31, 2017, and 2016, respectively.

Intangible Assets

Intangible assets

Amortization expense was $540,000 and $278,000 for the years ended December 31, 2017 and 2016, respectively.

Goodwill

Contingent Consideration

Contingent consideration

Common Stock Warrant Liability

Common stock warrant liability

Revenue Recognition

Foreign Currency Translation

Stock-Based Compensation

See Note 7- Stock Based Compensation, for further information regarding the assumptions used to calculate the fair value of share-based compensation.

Income Taxes

Loss per Share

Loss per share

	December 31,
	2017		2016
Stock options		36,362		4,354
Restricted stock units		245		499
Warrants to purchase common stock		8,522,684		44,268
Series B, C and D convertible preferred stock		—		53,179
Series F convertible preferred stock		842,940		—-
Total		9,402,231		102,300

The following table reconciles reported net loss with reported net loss per share for the years ended December 31:

(in thousands, except per share amounts)	2017			2016
Net loss	$	(13,382	)	$	(15,792	)
Deemed dividend to preferred shareholders (see Note 6)		(11,590	)		(1,900	)
Net loss after deemed dividend		(24,972	)		(17,692	)
Weighted average shares outstanding		665			33
Basic and diluted loss per share	$	(37.51	)	$	(536.12	)

Research and Development

Reclassification

Recent Accounting Pronouncements

The Company evaluates events through the date the consolidated financial statements are filed for events requiring adjustment to or disclosure in the consolidated financial statements.

Nature of Business and Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2017

Nature of Business and Significant Accounting Policies [Abstract]

Schedule of Inventories

Inventories are recorded as the lower of cost or market using the first-in, first out method. Inventories consisted of the following as of December 31 (in thousands):

	2017		2016
Finished Goods	$	902	$	644
Work in Process		217		—
Raw Materials		469		33
Total	$	1,588	$	677

Summary of Estimated Useful Lives

Depreciation expense has been calculated using the following estimated useful lives:

Office furniture and equipment	5-15 years
Computer software and equipment	3-4 years
Laboratory and research equipment	3-15 years
Production equipment	3-7 years
Leasehold improvements and capital lease asset	3-5 years

Potential Shares of Common Stock not Included in Diluted Net Loss Per Share

	December 31,
	2017		2016
Stock options		36,362		4,354
Restricted stock units		245		499
Warrants to purchase common stock		8,522,684		44,268
Series B, C and D convertible preferred stock		—		53,179
Series F convertible preferred stock		842,940		—-
Total		9,402,231		102,300

Schedule of Reconciles Reported Net Loss with Reported Net Loss Per Share

The following table reconciles reported net loss with reported net loss per share for the years ended December 31:

(in thousands, except per share amounts)	2017			2016
Net loss	$	(13,382	)	$	(15,792	)
Deemed dividend to preferred shareholders (see Note 6)		(11,590	)		(1,900	)
Net loss after deemed dividend		(24,972	)		(17,692	)
Weighted average shares outstanding		665			33
Basic and diluted loss per share	$	(37.51	)	$	(536.12	)

Aquadex Acquisition (Tables)

12 Months Ended

Dec. 31, 2017

Aquadex Acquisition [Abstract]

Purchase Consideration for Business

Purchase Consideration: Total purchase consideration for the Aquadex Business was as follows:

(in thousands)
Cash consideration	$	4,000
Common stock consideration		950
Fair value of contingent consideration		126
Total purchase consideration	$	5,076

Amount Recognized for Assets Acquired

The following presents the amounts recognized for the assets acquired on August 5, 2016 (in thousands):

Capital lease asset	$	307
Intangible assets		4,580
Total identifiable assets acquired		4,887
Goodwill		189
Total purchase consideration	$	5,076

Summary of Pro Forma Information

Twelve months ended December 31, 2016 (in thousands, except share amounts)
Pro forma net sales	$	3,160
Pro forma net loss from operations		(15,340	)
Pro forma basic and diluted net loss per share	$	(464.84	)

Property, Plant and Equipment (Tables)

12 Months Ended

Dec. 31, 2017

Property, Plant and Equipment [Abstract]

Summary of Property, Plant and Equipment

Property, plant and equipment were as follows:

(in thousands)	December 31, 2017			December 31, 2016
Office Furniture & Fixtures	$	287		$	280
Leasehold Improvements		224			145
Software		129			124
Production Equipment		926			968
Computer Equipment		277			245
Capital Lease Asset		307			307
Total		2,150			2,069
Accumulated Depreciation		(1,580	)		(1,529	)
	$	570		$	540

Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2017

Intangible Assets [Abstract]

Summary of Intangible Assets

Intangible assets were as follows:

(in thousands)	December 31, 2017			December 31, 2016
Customer Relationships	$	3,090		$	3,090
Developed Technology		1,050			1,050
Trade Names and Trademarks		440			440
Total		4,580			4,580
Accumulated Amortization		(818	)		(278	)
Impairment Charge		(3,762	)		—
	$	—		$	4,302

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2017

Stock-Based Compensation [Abstract]

Summary of Stock-Based Compensation Expense

The following table summarizes the stock-based compensation expense which was recognized in the consolidated statements of operations for the years ended December 31,

(Dollars in thousands)	2017		2016
Selling, general and administrative	$	452	$	630
Research and development		50		385
Total	$	502	$	1,015

Summary of Plan Stock Option Activity

The following is a summary of the Plans’ stock option activity during the years ended December 31:

	2017					2016
	Options Outstanding			Weighted Average Exercise Price		Options Outstanding			Weighted Average Exercise Price
Beginning Balance		4,354		$	2,295.37		3,260		$	3,664.61
Granted		34,651		$	11.57		2,257		$	543.63
Exercised		—			—		—			—
Forfeited/expired		(2,643	)	$	2,666.48		(1,163	)	$	2,729.60
Outstanding at December 31		36,362		$	91.48		4,354		$	2,295.37
Vested at December 31		2,344		$	964.27		2,134		$	3,780.79

Schedule of Weighted Average Assumptions used in Black-Scholes Option Pricing Model

The following table provides the weighed average assumptions used in the Black-Scholes option pricing model for the years ended December 31:

	2017			2016
Expected dividend yield		0	%		0	%
Risk-free interest rate		1.97	%		1.71	%
Expected volatility		103	%		86	%
Expected life (in years)		6.25			6.25

Summary of Restricted Stock Award Activity

The following table summarizes restricted stock award activity during 2017 and 2016:

	2017					2016
	RSUs			Weighted Average Grant Price		RSUs			Weighted Average Grant Price
Nonvested, beginning balance		499		$	583.29		15		$	2,574.00
Granted		138		$	108.20		1,131		$	553.88
Vested		(392	)	$	132.70		(619	)	$	443.40
Forfeited		—			—		(28	)	$	426.00
Nonvested at December 31		245		$	521.23		499		$	583.29

Fair Value of Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2017

Fair Value of Financial Instruments [Abstract]

Fair value of common stock warrant liability calculated Black Scholes option pricing model classified as Level 3 in fair value hierarchy

The following is a rollfoward of the fair value of Level 3 warrants:

(in thousands)
July 26, 2016 warrant issuance	$	1,883
November 3, 2016 warrant issuance		778
Change in fair value		(818	)
Ending balance December 31, 2016		1,843
Change in fair value		(1,475	)
Exercise of warrants		(368	)
Ending balance as of December 31, 2017	$	—

Summary of Fair Value Assumptions Used in Calculation of Monte Carlo Valuation Model

Fair values were calculated using the following assumptions:

	July 26, 2016			Nov. 3, 2016			Dec. 31, 2016
Risk-free interest rates, adjusted for continuous compounding		0.94	%		1.33	%		1.47/1.96	%
Term (years)		3.5			5.5			3.1/5.3
Expected volatility		78	%		41.4	%		55.3/49.8	%
Dates and probability of future equity raises		various			various			various

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2017

Income Taxes [Abstract]

Summary of Domestic and Foreign Loss Before Income Taxes

Domestic and foreign loss before income taxes, consists of the following for the years ended December 31:

(in thousands)	2017			2016
Domestic	$	(13,367	)	$	(15,877	)
Foreign		(9	)		31
Loss before income taxes	$	(13,376	)	$	(15,846	)

Summary of Components of Income Tax Benefit (Expense)

The components of income tax benefit (expense) consist of the following for the years ended December 31:

(in thousands)	2017			2016
Current:
United States and state	$	—		$	—
Foreign, net		(6	)		54
Deferred:
United States and state		—			—
Foreign		—			—
Total income tax benefit (expense)	$	(6	)	$	54

Summary of Actual Income Tax Benefit (Expense) Differs from Statutory Federal Income Tax Benefit (Expense)

Actual income tax benefit (expense) differs from statutory federal income tax benefit (expense) as follows for the years ended December 31:

(in thousands)	2017			2016
Statutory federal income tax benefit	$	4,548		$	5,388
State tax benefit, net of federal taxes		48			2
Foreign tax		—			3
R&D tax credit		—			80
Foreign deferred exchange rate adjustments		899			—
Nondeductible/nontaxable items		(114	)		(86	)
New federal rate adjustment		(16,081	)		—
Other		(1,085	)		(257	)
Valuation allowance decrease (increase)		11,779			(5,076	)
Total income tax benefit (expense)	$	(6	)	$	54

Summary of Components of Deferred Taxes

Deferred taxes consist of the following as of December 31:

(in thousands)	2017			2016
Deferred tax assets:
Noncurrent:
Accrued leave	$	32		$	43
Other accrued expenses		28			97
Stock based compensation		336			1,477
Net operating loss carryforward		38,947			49,720
Deferred rent		7			17
Other		108			777
Intangibles		895
R&D credit carryforward		531			531
Total deferred tax assets	$	40,884		$	52,662
Less: valuation allowance		(40,884	)		(52,662	)
Total	$	—		$	—

Nature of Business and Significant Accounting Policies, Nature of Business, Going Concern, Accounts Receivable and Inventory (Details)					1 Months Ended	12 Months Ended
	Nov. 27, 2017 USD ($)	Oct. 12, 2017	Apr. 24, 2017 USD ($)	Jan. 12, 2017	Mar. 31, 2016 Study	Dec. 31, 2017 USD ($) StockSplit	Dec. 31, 2016 USD ($)
Nature of Business [Abstract]
Number of clinical studies for C-Pulse System \| Study					2
Number of reverse stock split \| StockSplit						2
Reverse stock split ratio		20		30
Going Concern [Abstract]
Retained earnings (accumulated deficit)						$ (182,356,000)	$ (168,974,000)
Net proceeds from issuance of convertible preferred stock	$ 16,200,000		$ 8,000,000
Accounts Receivable [Abstract]
Accounts receivables maximum credit period from invoice date						30 days
Allowance for doubtful accounts						$ 0	0
Inventory [Abstract]
Finished Goods						902,000	644,000
Work in Process						217,000	0
Raw Materials						469,000	33,000
Total						$ 1,588,000	$ 677,000

Nature of Business and Significant Accounting Policies, Property, Plant and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 229	$ 419
Impairment losses recognized	$ 0	$ 0
Office Furniture and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	5 years
Office Furniture and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	15 years
Computer Software and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	3 years
Computer Software and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	4 years
Laboratory and Research Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	3 years
Laboratory and Research Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	15 years
Production Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	3 years
Production Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	7 years
Leasehold Improvements and Capital Lease Asset [Member] \| Minimum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	3 years
Leasehold Improvements and Capital Lease Asset [Member] \| Maximum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	5 years

Nature of Business and Significant Accounting Policies, Intangible assets and Goodwill (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Impairment charges related to finite-lived intangible assets	$ 3,800,000
Amortization expense	$ 540,000	$ 278,000
Overall discount rate	30.00%
Goodwill [Abstract]
Goodwill impairment loss	$ 200,000
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	7 years
Overall discount rate	30.00%
Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	7 years
Overall discount rate	30.00%
Trade Names and Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	7 years
Overall discount rate	30.00%

Nature of Business and Significant Accounting Policies, Income Taxes and Loss Per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Line Items]
U.S. corporate income tax rate		34.00%
Percentage of valuation allowance on deferred tax assets		100.00%
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)		9,402,231	102,300
Reported net loss with reported net loss per share [Abstract]
Net loss		$ (13,382,000)	$ (15,792,000)
Deemed dividend to preferred shareholders (see Note 6)		(11,590,000)	(1,900,000)
Net loss after deemed dividend		$ (24,972,000)	$ (17,692,000)
Weighted average shares outstanding (in shares)		665,000	33,000
Basic and diluted loss per share (in dollars per share)		$ (37.51)	$ (536.12)
Series E Convertible Preferred Stock [Member]
Reported net loss with reported net loss per share [Abstract]
Deemed dividend to preferred shareholders (see Note 6)		$ (1,000,000)
Series F Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)		842,940	0
Reported net loss with reported net loss per share [Abstract]
Deemed dividend to preferred shareholders (see Note 6)		$ (8,700,000)
Series C and D Convertible Preferred Stock [Member]
Reported net loss with reported net loss per share [Abstract]
Deemed dividend to preferred shareholders (see Note 6)		(1,800,000)
Series B and B-1 Convertible Preferred Stock [Member]
Reported net loss with reported net loss per share [Abstract]
Deemed dividend to preferred shareholders (see Note 6)		$ (1,900,000)	$ (1,900,000)
Series B, C And D Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)		0	53,179
Plan [Member]
Income Tax Disclosure [Line Items]
U.S. corporate income tax rate	21.00%
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)		36,362	4,354
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)		245	499
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)		8,522,684	44,268

Aquadex Acquisition (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Aug. 05, 2016	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition [Line Item]
Revenue		$ 3,553	$ 1,289
Amounts recognized for assets acquired [Abstract]
Goodwill		0	189
Aquadex Product Line [Member]
Business Acquisition [Line Item]
Revenue		$ 3,600	1,200
Total purchase consideration [Abstract]
Cash consideration	$ 4,000
Common stock consideration	950
Fair value of contingent consideration	126
Total purchase consideration	$ 5,076
Common stock issued in acquisition (in shares)	1,666
Closing market value (in dollars per share)	$ 570
Contingent consideration payable in excess of sale or disposal of business assets	40.00%
Sale or disposal of business assets threshold for contingent consideration	$ 4,000
Acquisition related expenses	900
Amounts recognized for assets acquired [Abstract]
Capital lease asset	307
Intangible assets	4,580
Total identifiable assets acquired	4,887
Goodwill	189
Total purchase consideration	$ 5,076
Pro forma information [Abstract]
Pro forma net sales			3,160
Pro forma net loss from operations			$ (15,340)
Pro forma basic and diluted net loss per share (in dollars per share)			$ (464.84)
Aquadex Product Line [Member] \| Maximum [Member]
Business Acquisition [Line Item]
Agreement term		18 months
Total purchase consideration [Abstract]
Contingent consideration period		3 years

Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 2,150	$ 2,069
Accumulated Depreciation	(1,580)	(1,529)
Property, Plant and Equipment, Net	570	540
Office Furniture & Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	287	280
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	224	145
Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	129	124
Production Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	926	968
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	277	245
Capital Lease Asset [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 307	$ 307

Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 4,580	$ 4,580
Accumulated Amortization	(818)	(278)
Impairment Charge	(3,762)	0
Intangible Assets, Net	$ 0	4,302
Discount rate	30.00%
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 3,090	3,090
Discount rate	30.00%
Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 1,050	1,050
Discount rate	30.00%
Trade Names and Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 440	$ 440
Discount rate	30.00%

Debt, Prior Loan Agreement (Details) $ in Thousands					12 Months Ended
Debt, Prior Loan Agreement (Details) $ in Thousands	Aug. 04, 2016 USD ($)	Jan. 01, 2016 Installment	Jun. 26, 2015 USD ($)	Feb. 18, 2015 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Debt Instrument [Line Items]
Maximum borrowing capacity					$ 5,000
Repayment of outstanding debt					0	$ (8,000)
Loss on early retirement of long-term debt					0	(500)
Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity				$ 10,000
Annual interest rate				7.00%
Proceeds from term loan used for general corporate and working capital			$ 2,000	$ 6,000
Consecutive equal monthly installments \| Installment		24
Repayment of outstanding debt	$ (5,500)
Loss on early retirement of long-term debt	$ (500)
Total borrowings outstanding					$ 0	$ 0

- Definition

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References + Details

Debt, Warrants (Details) - $ / shares			12 Months Ended
Debt, Warrants (Details) - $ / shares	Nov. 03, 2016	Jul. 26, 2016	Dec. 31, 2017
Debt Instrument [Line Items]
Expected stock price volatility	41.40%	78.00%
Risk-free interest rate	1.33%	0.94%
Expected warrant option life	5 years 6 months	3 years 6 months
Affiliates [Member]
Debt Instrument [Line Items]
Warrants issued (in shares)			55
Exercise price of warrants (in dollars per share)			$ 2,208
Value of warrants (in dollars per share)			$ 1,626
Expected dividend yield			0.00%
Expected stock price volatility			87.04%
Risk-free interest rate			2.20%
Expected warrant option life			6 years 3 months
Term of warrants			10 years
Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Warrants issued (in shares)			115
Exercise price of warrants (in dollars per share)			$ 3,132
Value of warrants (in dollars per share)			$ 2,316
Expected dividend yield			0.00%
Expected stock price volatility			88.07%
Risk-free interest rate			1.86%
Expected warrant option life			6 years 3 months
Term of warrants			10 years

Debt, New Loan Agreement (Details) - USD ($) $ in Millions	12 Months Ended
Debt, New Loan Agreement (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 5.0
Term Loan [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 4.0
Maturity date	Nov. 30, 2016
Revolving Line [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 1.0
Maturity date	Mar. 31, 2020
Total borrowings outstanding	$ 0.0	$ 0.0
Revolving Line [Member] \| Floating Annual Rate [Member]
Debt Instrument [Line Items]
Interest rate	1.75%
Revolving Line [Member] \| Prime Rate [Member]
Debt Instrument [Line Items]
Interest rate	1.00%

- Definition

+ References + Details

Shareholder's Equity, Convertible Preferred Stock (Details) - USD ($)								12 Months Ended
	Nov. 27, 2017	Apr. 24, 2017	Jan. 10, 2017	Nov. 03, 2016	Oct. 30, 2016	Jul. 26, 2016	Jul. 20, 2016	Dec. 31, 2017	Dec. 31, 2016
Class of Stock [Line Items]
Proceeds from issuance of convertible preferred stock and Warrants					$ 3,800,000		$ 3,500,000
Net proceeds from issuance of convertible preferred stock	$ 16,200,000	$ 8,000,000
Preferred stock, shares outstanding (in shares)								0	0
Net deemed dividend								$ (11,590,000)	$ (1,900,000)
Common stock, shares issued (in shares)								3,798,929	38,862
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued (in shares)						3,468
Number of preferred shares converted to common stock (in shares)						6,149
Conversion price (in dollars per share)						$ 564.0
Proceed from issuance of preferred stock						$ 1,600,000
Series B-1 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued (in shares)					2,227.2			0	1,824.4
Number of preferred shares converted to common stock (in shares)								17,866	3,948
Conversion price (in dollars per share)					$ 102
Number of convertible preferred shares converted (in shares)									402.8
Preferred stock, shares outstanding (in shares)								0	1,824.4
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued (in shares)				2,900				0	2,900
Number of preferred shares converted to common stock (in shares)									0
Conversion price (in dollars per share)				$ 102
Preferred stock, shares outstanding (in shares)								0	2,900
Beneficial conversion amount			$ 1,300,000
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Proceeds from issuance of convertible preferred stock and Warrants			$ 200,000
Preferred stock, shares issued (in shares)			200
Number of preferred shares converted to common stock (in shares)									0
Conversion price (in dollars per share)			$ 102	$ 102
Temporary stock, shares issued (in shares)				700				0	700
Beneficial conversion amount			$ 500,000
Temporary stock, shares outstanding (in shares)								0	700
Temporary equity								$ 0	$ 485,000
Series C and D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Proceeds from issuance of convertible preferred stock and Warrants				$ 3,600,000
Number of preferred shares converted to common stock (in shares)								55,712
Temporary stock, shares outstanding (in shares)								0
Series B and B-1 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Net deemed dividend								$ (1,900,000)	$ (1,900,000)
Series B, C And D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Percentage of placement fee offered in cash								6.00%
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued (in shares)								6,400
Number of preferred shares converted to common stock (in shares)								320,000
Proceed from issuance of preferred stock		9,200,000
Net proceeds from issuance of convertible preferred stock		$ 8,000,000
Preferred stock, shares outstanding (in shares)								0
Beneficial conversion amount								$ 1,000,000
Percentage of placement fee offered in cash								9.00%
Net deemed dividend								$ (1,000,000)
Common stock, shares issued (in shares)								140,000
Series E Convertible Preferred Stock [Member] \| Warrants [Member]
Class of Stock [Line Items]
Warrants to purchase shares of common stock (in shares)								640,000
Warrants issued to the placement agent (in shares)								0
Class A Units [Member]
Class of Stock [Line Items]
Public offering price (in dollars per share)								$ 20.00
Number of common stock (in shares)								1
Class A Units [Member] \| Warrants [Member]
Class of Stock [Line Items]
Number of preferred shares converted to common stock (in shares)								1
Term of warrants								5 years
Number of warrants (in shares)								1
Exercise price of warrants (in dollars per share)								$ 22
Class B Units [Member]
Class of Stock [Line Items]
Number of preferred shares converted to common stock (in shares)								50
Public offering price (in dollars per share)								$ 1,000
Number of preferred stock per unit (in shares)								1
Class B Units [Member] \| Warrants [Member]
Class of Stock [Line Items]
Warrants to purchase shares of common stock (in shares)								50
Exercise price of warrants (in dollars per share)								$ 22
Series F Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued (in shares)	18,000							3,780	0
Number of preferred shares converted to common stock (in shares)	4,000,000							3,171,060
Conversion price (in dollars per share)	$ 4.50
Number of convertible preferred shares converted (in shares)								14,220
Proceed from issuance of preferred stock	$ 18,000,000
Net proceeds from issuance of convertible preferred stock	16,200,000
Preferred stock, shares outstanding (in shares)								3,780	0
Beneficial conversion amount	$ 8,700,000
Percentage of placement fee offered in cash								8.00%
Net deemed dividend								$ (8,700,000)
Series F Convertible Preferred Stock [Member] \| Warrants [Member]
Class of Stock [Line Items]
Warrants to purchase shares of common stock (in shares)	8,000,000
Warrants issued to the placement agent (in shares)								0
Series F Convertible Preferred Stock [Member] \| Warrant Series 1 [Member]
Class of Stock [Line Items]
Number of preferred shares converted to common stock (in shares)	223
Exercise price of warrants (in dollars per share)	$ 4.50
Series F Convertible Preferred Stock [Member] \| Warrant Series 2 [Member]
Class of Stock [Line Items]
Number of preferred shares converted to common stock (in shares)	223
Exercise price of warrants (in dollars per share)	$ 4.50

Shareholder's Equity, Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands				2 Months Ended	12 Months Ended
	Jan. 10, 2017	Nov. 03, 2016	Jul. 26, 2016	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Class of Stock [Line Items]
Proceeds from exercise of warrants					$ 1,989	$ 0
Warrants outstanding					0	1,843
Change in fair value of warrant liability					1,475	$ 818
Expected stock price volatility		41.40%	78.00%
Risk-free interest rate		1.33%	0.94%
Expected warrant option life		5 years 6 months	3 years 6 months
Minimum [Member]
Class of Stock [Line Items]
Expected stock price volatility						55.30%
Risk-free interest rate						1.47%
Expected warrant option life						3 years 1 month 6 days
Maximum [Member]
Class of Stock [Line Items]
Expected stock price volatility						49.80%
Risk-free interest rate						1.96%
Expected warrant option life						5 years 3 months 18 days
Replacement Warrants [Member]
Class of Stock [Line Items]
Warrants outstanding					$ 500
Expected dividend yield					0.00%
Expected warrant option life					5 years
Replacement Warrants [Member] \| Minimum [Member]
Class of Stock [Line Items]
Expected stock price volatility					49.65%
Risk-free interest rate					1.95%
Replacement Warrants [Member] \| Maximum [Member]
Class of Stock [Line Items]
Expected stock price volatility					50.38%
Risk-free interest rate					1.97%
Series B Convertible Preferred Stock [Member] \| Investor Warrants [Member]
Class of Stock [Line Items]
Warrants issuance cost			$ 0
Warrants to purchase shares of common stock (in shares)			6,149
Exercise price of warrants (in dollars per share)			$ 564
Warrants exercisable period					36 months
Period warrants became exercisable from closing date					6 months
Series D Convertible Preferred Stock [Member] \| Investor Warrants [Member]
Class of Stock [Line Items]
Warrants issuance cost	$ 0
Warrants to purchase shares of common stock (in shares)	1,961
Exercise price of warrants (in dollars per share)	$ 108
Warrants exercisable period					60 months
Period warrants became exercisable from closing date					6 months
Series C and D Convertible Preferred Stock [Member] \| Investor Warrants [Member]
Class of Stock [Line Items]
Warrants issuance cost		$ 0
Warrants to purchase shares of common stock (in shares)		35,295
Exercise price of warrants (in dollars per share)		$ 108
Adjusted exercise price of warrants (in dollars per share)		$ 102
Warrant Exercise Agreement [Member] \| Original Warrants [Member]
Class of Stock [Line Items]
Proceeds from exercise of warrants				$ 2,000
Warrants outstanding					$ 0
Relinquished amount of warrants					$ 100
Warrant Exercise Agreement [Member] \| Replacement Warrants [Member]
Class of Stock [Line Items]
Warrants to purchase shares of common stock (in shares)				43,396
Warrant Exercise Agreement [Member] \| Replacement Warrants [Member] \| Minimum [Member]
Class of Stock [Line Items]
Exercise price of warrants (in dollars per share)				$ 34.6
Warrant Exercise Agreement [Member] \| Replacement Warrants [Member] \| Maximum [Member]
Class of Stock [Line Items]
Exercise price of warrants (in dollars per share)				$ 99.8

Stock-Based Compensation, Stock Options and Restricted Stock Awards (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 502,000	$ 1,015,000
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	1 year
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years
Selling, General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 452,000	630,000
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 50,000	$ 385,000
Stock Options [Member]
Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding, beginning balance (in shares)	4,354	3,260
Granted (in shares)	34,651	2,257
Exercised (in shares)	0	0
Forfeited/expired (in shares)	(2,643)	(1,163)
Outstanding, ending balance (in shares)	36,362	4,354
Vested at the end of the year (in shares)	2,344	2,134
Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding at the beginning of the year (in dollars per share)	$ 2,295.37	$ 3,664.61
Granted (in dollars per share)	11.57	543.63
Exercised (in dollars per share)	0	0
Forfeited/expired (in dollars per share)	2,666.48	2,729.60
Outstanding at the end of the year (in dollars per share)	91.48	2,295.37
Vested at the end of the year (in dollars per share)	$ 964.27	$ 3,780.79
Share Based Payment Award, Options Weighted Average Remaining Contractual Term [Abstract]
Options outstanding, weighted average remaining contractual life	9 years 3 months 29 days
Options vested, weighted average remaining contractual life	8 years 3 months 14 days
Share Based Payment Award, Aggregate Intrinsic Value [Abstract]
Fair value of options, vested	$ 700,000	$ 1,100,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expected dividend yield	0.00%	0.00%
Risk-free interest rate	1.97%	1.71%
Expected volatility	103.00%	86.00%
Expected life	6 years 3 months	6 years 3 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted-average fair value of options granted (in dollars per share)	$ 11.97	$ 543.63
Total unrecognized compensation costs related to non-vested stock option awards	$ 744,000
Unrecognized compensation costs related to non-vested stock option awards, recognition period	3 years 1 month 6 days
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested beginning balance (in shares)	499	15
Granted (in shares)	138	1,131
Vested (in shares)	(392)	(619)
Forfeited (in shares)	0	(28)
Nonvested ending balance (in shares)	245	499
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Nonvested weighted average grant price beginning balance (in dollars per share)	$ 583.29	$ 2,574.00
Granted (in dollars per share)	108.20	553.88
Vested (in dollars per share)	132.70	443.40
Forfeited (in dollars per share)	0	426.00
Nonvested weighted average grant price ending balance (in dollars per share)	$ 521.23	$ 583.29
Employees tendered restricted stock units (in shares)	15	165

Stock-Based Compensation, Warrants (Details) - Warrants [Member] - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares)	8,522,684	44,268
Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise price of warrants (in dollars per share)	$ 4.50
Warrants exercisable period	11 months
Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise price of warrants (in dollars per share)	$ 383.57
Warrants exercisable period	7 years 6 months

Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands			2 Months Ended	12 Months Ended
	Nov. 03, 2016	Jul. 26, 2016	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Fair value of Level 3 [Roll Forward]
Warrant issuance				$ 509	$ 0
Change in fair value				1,475	818
Ending balance			$ 1,843	0	1,843
Fair Value Assumptions [Abstract]
Risk-free interest rates, adjusted for continuous compounding	1.33%	0.94%
Term	5 years 6 months	3 years 6 months
Expected volatility	41.40%	78.00%
Fair Value Transfers between levels [Abstract]
Level 1 to Level 2 Asset Transfers			0	0	0
Level 2 to Level 1 Asset Transfers			0	0	0
Level 1 to Level 2 Liability Transfers			0	0	0
Level 2 to Level 1 Liability Transfers			0	0	$ 0
Minimum [Member]
Fair Value Assumptions [Abstract]
Risk-free interest rates, adjusted for continuous compounding					1.47%
Term					3 years 1 month 6 days
Expected volatility					55.30%
Maximum [Member]
Fair Value Assumptions [Abstract]
Risk-free interest rates, adjusted for continuous compounding					1.96%
Term					5 years 3 months 18 days
Expected volatility					49.80%
Level 3 [Member]
Fair value of Level 3 [Roll Forward]
Change in fair value			(818)	(1,475)
Exercise of warrants				(368)
Ending balance			$ 1,843	$ 0	$ 1,843
Level 3 [Member] \| Warrants Issued July 26 2016 [Member]
Fair value of Level 3 [Roll Forward]
Warrant issuance		$ 1,883
Level 3 [Member] \| Warrants Issued November 3 2016 [Member]
Fair value of Level 3 [Roll Forward]
Warrant issuance	$ 778

Income Taxes, Domestic and Foreign Loss Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Loss before income taxes [Abstract]
Domestic	$ (13,367)	$ (15,877)
Foreign	(9)	31
Loss before income taxes	$ (13,376)	$ (15,846)

Income Taxes, Components of Income Tax Benefit (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Current [Abstract]
United States and state	$ 0	$ 0
Foreign, net	(6)	54
Deferred [Abstract]
United States and state	0	0
Foreign	0	0
Total income tax benefit (expense)	$ (6)	$ 54

Income Taxes, Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Effective income tax rate reconciliation [Abstract]
Statutory federal income tax benefit	$ 4,548	$ 5,388
State tax benefit, net of federal taxes	48	2
Foreign tax	0	3
R&D tax credit	0	80
Foreign deferred exchange rate adjustments	899	0
Nondeductible/nontaxable items	(114)	(86)
New federal rate adjustment	(16,081)	0
Other	(1,085)	(257)
Valuation allowance decrease (increase)	11,779	(5,076)
Total income tax benefit (expense)	$ (6)	$ 54

Income Taxes, Deferred Taxes and Other Information (Details) $ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2017 AUD ($)	Dec. 31, 2016 AUD ($)
Noncurrent [Abstract]
Accrued leave		$ 32	$ 43
Other accrued expenses		28	97
Stock based compensation		336	1,477
Net operating loss carryforward		38,947	49,720
Deferred rent		7	17
Other		108	777
Intangibles		895
R&D credit carryforward		531	531
Total deferred tax assets		40,884	52,662
Less: valuation allowance		(40,884)	(52,662)
Total		$ 0	0
Income Tax Disclosure [Line Items]
U.S. corporate income tax rate		34.00%
Percentage of valuation allowance on deferred tax assets		100.00%
Operating Loss Carryforwards [Line Items]
Uncertain tax positions		$ 0	0
Interest and penalties related to uncertain tax positions accrued during the period		0	$ 0
Research Tax Credit Carryforward [Member] \| Australian Taxation Office [Member]
Tax Credit Carryforward [Line Items]
Fully refundable research and development tax credits				$ 0	$ 80
Plan [Member]
Income Tax Disclosure [Line Items]
U.S. corporate income tax rate	21.00%
United States [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss (NOL) carryforwards		$ 120,200
Australian [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss (NOL) carryforwards				$ 49,000

Commitments and Contingencies - (Details) - USD ($)		12 Months Ended
Commitments and Contingencies - (Details) - USD ($)	Aug. 05, 2016	Dec. 31, 2017	Dec. 31, 2016	Jun. 30, 2017
Leases [Abstract]
Rent expense related to operating leases		$ 290,000	$ 286,000
Future minimum lease payments [Abstract]
2018		212,000
2019		60,000
2020		7,000
2021		0
2022		0
Employee Retirement Plan [Abstract]
Employer's matching contribution		138,000	$ 122,000
Aquadex Product Line [Member]
Inventory Purchase Commitments [Abstract]
Remaining inventory obligation		1,200,000		$ 2,400,000
Inventory purchases		$ 1,200,000
Contingent Consideration [Abstract]
Sale or disposal of business assets threshold for contingent consideration	$ 4,000,000
Percentage of additional payments on disposes of business assets	40.00%
Aquadex Product Line [Member] \| Maximum [Member]
Inventory Purchase Commitments [Abstract]
Agreement term		18 months
Contingent Consideration [Abstract]
Contingent consideration period		3 years

Segment and Geographic Information (Details)	12 Months Ended
Segment and Geographic Information (Details)	Dec. 31, 2017 Segment
Segment and Geographic Information [Abstract]
Number of reportable segments	1